Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07013565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Study acronym: ACCELERATE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruiting
    • Eligibility criteria expanded, about 72 words
    • Site details revised
    v3
  2. Primary endpoints: 4 to 5v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jul 1, 2025 to Aug 7, 2025
    • Site contact updated
    • Collaborators: 6 to 10
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.
Trial Details
NCT Number NCT07013565
Lead Sponsor New York Medical College
Collaborators: University of Alabama at Birmingham, Helen DeVos Children's Hospital, Nationwide Children's Hospital, Memorial Sloan Kettering Cancer Center, University of Utah, Ohio State University, University of North Carolina, Children's Hospital of Philadelphia, Medical College of Wisconsin, Children's Hospital of Orange County
Conditions
(from sponsor)		 Anaplastic Large Cell Lymphoma, ALK-Positive
Related terms Lymphoma, Large-Cell, Anaplastic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov